PGⅠ、PGⅡ、G-17检测在胃癌及萎缩性胃炎诊断中的应用价值
|
摘要
目的探讨胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)、胃泌素17(G-17)检测在胃癌及萎缩性胃炎诊断中的应用价值。方法选取我院2016年8月～2018年1月收治的120例胃炎、胃癌患者作为研究对象,按照患者疾病情况分为A组(萎缩性胃炎40例)、B组(浅表性胃炎40例)、C组(胃癌40例),分析上述患者的血清PGⅠ、PGⅡ、G-17水平。结果 B组患者的PGⅠ、PGⅡ水平明显高于其他两组,且A组患者的PGⅠ、PGⅡ水平高于C组患者,差异有统计学意义(P<0.05)。C组患者的G-17水平明显高于其他两组,但是C组患者的PGR水平则明显低于其他两组患者(P<0.05)。同时Hp显示阳性患者的PGⅠ、PGⅡ水平明显高于Hp阴性患者(P<0.05)。结论对于萎缩性胃炎的患者,采用PGⅠ、PGⅡ联合G-17检测进行早期诊断,能有效反映胃黏膜的病变情况,可以对早期胃癌的诊断提供准确数据,为临床治疗提供保障。
Objective To investigate the application value of PG Ⅰ, PGⅡ and G-17 in the diagnosis of gastric cancer and atrophic gastritis. Methods A total of 120 patients with gastritis and gastric cancer admitted to our hospital from August 2016 to January 2018 were selected and divided into group A(40 patients with atrophic gastritis), group B(40 patients with superficial gastritis) and group C(40 patients with gastric cancer) according to the patient′s disease condition. The serum levels of PG Ⅰ, PG Ⅱ and G-17 were analyzed. Results The levels of PGⅠ and PGⅡ in group B were significantly higher than those in other two groups, and the levels of PGⅠ and PGⅡ in group A were significantly higher than those in group C, with significant difference(P<0.05). The levels of G-17 in group C were significantly higher than those in other two groups, but the levels of PGR in group C were significantly lower than those in other two groups(P<0.05). At the same time, the levels of PGⅠ and PGⅡ in Hp-positive patients were significantly higher than those in Hp-negative patients(P <0.05). Conclusion PG Ⅰ, PG Ⅱ combined with G-17 can effectively reflect the pathological changes of gastric mucosa in patients with atrophic gastritis, and provide accurate data for the diagnosis of early gastric cancer, and provide a guarantee for clinical treatment.
Objective To investigate the application value of PG Ⅰ, PGⅡ and G-17 in the diagnosis of gastric cancer and atrophic gastritis. Methods A total of 120 patients with gastritis and gastric cancer admitted to our hospital from August 2016 to January 2018 were selected and divided into group A(40 patients with atrophic gastritis), group B(40 patients with superficial gastritis) and group C(40 patients with gastric cancer) according to the patient′s disease condition. The serum levels of PG Ⅰ, PG Ⅱ and G-17 were analyzed. Results The levels of PGⅠ and PGⅡ in group B were significantly higher than those in other two groups, and the levels of PGⅠ and PGⅡ in group A were significantly higher than those in group C, with significant difference(P<0.05). The levels of G-17 in group C were significantly higher than those in other two groups, but the levels of PGR in group C were significantly lower than those in other two groups(P<0.05). At the same time, the levels of PGⅠ and PGⅡ in Hp-positive patients were significantly higher than those in Hp-negative patients(P <0.05). Conclusion PG Ⅰ, PG Ⅱ combined with G-17 can effectively reflect the pathological changes of gastric mucosa in patients with atrophic gastritis, and provide accurate data for the diagnosis of early gastric cancer, and provide a guarantee for clinical treatment.
引文
[1]梁静.血清胃蛋白酶原联合胃泌素测定在胃癌及萎缩性胃炎中的诊断价值[J].健康之路,2017,16(9):222.
[2]薛辉,辛凤池,穆素恩,等.血清胃蛋白酶原联合G-17对萎缩性胃炎及胃癌早期诊断价值[J].现代生物医学进展,2017,17(11):2119-2122.
[3]杨伟华,丁禹,袁妮娜.血清胃蛋白酶原胃泌素-17幽门螺杆菌IgG抗体联合检测在胃癌诊断中的临床价值[J].浙江临床医学,2017,19(10):1930-1931.
[4]张强,石新芳,袁向珍.联合检测血清胃蛋白酶原、胃泌素-17在萎缩性胃炎及胃癌筛查中的价值[J].中西医结合心血管病电子杂志,2017,5(20):178-179.
[5]闫真,邵淑琳,张杰,等.血清胃蛋白酶原联合胃泌素17检测在胃癌筛查中的价值[J].中国医药,2016,11(12):1795-1799.
[6]郭文涛,李继昌,刘海霞,等.血清胃蛋白酶原联合胃泌素17检测在不同胃黏膜病变诊断中的临床价值[J].临床合理用药杂志,2017,10(33):133-135.
[7]张华,乐嫣,张艺青,等.联合检测胃蛋白酶原、胃泌素-17及CEA、CA19-9在胃癌诊断中的应用[J].标记免疫分析与临床,2018,25(1):5-7,43.
[8]赵建业,朱春平,李兆申.血清胃蛋白酶原、胃泌素-17、幽门螺杆菌抗体检测对萎缩性胃炎和胃癌的诊断价值[J].胃肠病学,2016,21(6):376-379.
[9]张守彩,高玉,郑桂喜,等.两种方法评估胃蛋白酶原在萎缩性胃炎和胃癌中的诊断价值[J].山东大学学报(医学版),2016,54(12):46-52.
[10]徐育红,李艳丽,张雁.血清胃蛋白酶原与CA724联合检测在胃癌鉴别诊断中的应用价值[J].国际免疫学杂志,2017,40(4):401-403.
[11]江爱云.胃蛋白酶原在慢性萎缩性胃炎和胃癌早期诊断中的应用价值分析[J].医学理论与实践,2017,30(20):3084-3085.
[12]刘林杰,刘明军,王麟,等.血清胃蛋白酶原和胃泌素-17检测在胃癌筛查中的应用[J].检验医学与临床,2017,14(20):3044-3047.
[13]钱磊,陈为军.血清胃蛋白酶原在胃癌早期诊断中的应用意义及价值评析[J].中国实验诊断学,2016,20(2):243-245.
[14]盛秀红.血清胃蛋白酶原在慢性萎缩性胃炎和早期胃癌中的临床价值[J].医学检验与临床,2016,27(3):100-101.
[15]高洪亮,李宁,张清禄.血清PGI、PGⅡ及G-17检测在胃癌及萎缩性胃炎中诊断价值分析[J].癌症进展,2017,15(6):654-656.
[2]薛辉,辛凤池,穆素恩,等.血清胃蛋白酶原联合G-17对萎缩性胃炎及胃癌早期诊断价值[J].现代生物医学进展,2017,17(11):2119-2122.
[3]杨伟华,丁禹,袁妮娜.血清胃蛋白酶原胃泌素-17幽门螺杆菌IgG抗体联合检测在胃癌诊断中的临床价值[J].浙江临床医学,2017,19(10):1930-1931.
[4]张强,石新芳,袁向珍.联合检测血清胃蛋白酶原、胃泌素-17在萎缩性胃炎及胃癌筛查中的价值[J].中西医结合心血管病电子杂志,2017,5(20):178-179.
[5]闫真,邵淑琳,张杰,等.血清胃蛋白酶原联合胃泌素17检测在胃癌筛查中的价值[J].中国医药,2016,11(12):1795-1799.
[6]郭文涛,李继昌,刘海霞,等.血清胃蛋白酶原联合胃泌素17检测在不同胃黏膜病变诊断中的临床价值[J].临床合理用药杂志,2017,10(33):133-135.
[7]张华,乐嫣,张艺青,等.联合检测胃蛋白酶原、胃泌素-17及CEA、CA19-9在胃癌诊断中的应用[J].标记免疫分析与临床,2018,25(1):5-7,43.
[8]赵建业,朱春平,李兆申.血清胃蛋白酶原、胃泌素-17、幽门螺杆菌抗体检测对萎缩性胃炎和胃癌的诊断价值[J].胃肠病学,2016,21(6):376-379.
[9]张守彩,高玉,郑桂喜,等.两种方法评估胃蛋白酶原在萎缩性胃炎和胃癌中的诊断价值[J].山东大学学报(医学版),2016,54(12):46-52.
[10]徐育红,李艳丽,张雁.血清胃蛋白酶原与CA724联合检测在胃癌鉴别诊断中的应用价值[J].国际免疫学杂志,2017,40(4):401-403.
[11]江爱云.胃蛋白酶原在慢性萎缩性胃炎和胃癌早期诊断中的应用价值分析[J].医学理论与实践,2017,30(20):3084-3085.
[12]刘林杰,刘明军,王麟,等.血清胃蛋白酶原和胃泌素-17检测在胃癌筛查中的应用[J].检验医学与临床,2017,14(20):3044-3047.
[13]钱磊,陈为军.血清胃蛋白酶原在胃癌早期诊断中的应用意义及价值评析[J].中国实验诊断学,2016,20(2):243-245.
[14]盛秀红.血清胃蛋白酶原在慢性萎缩性胃炎和早期胃癌中的临床价值[J].医学检验与临床,2016,27(3):100-101.
[15]高洪亮,李宁,张清禄.血清PGI、PGⅡ及G-17检测在胃癌及萎缩性胃炎中诊断价值分析[J].癌症进展,2017,15(6):654-656.